NAT2 antibody (AA 171-290)
Quick Overview for NAT2 antibody (AA 171-290) (ABIN6144378)
Target
See all NAT2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 171-290
-
Sequence
- TNKEFLNSHL LPKKKHQKIY LFTLEPRTIE DFESMNTYLQ TSPTSSFITT SFCSLQTPEG VYCLVGFILT YRKFNYKDNT DLVEFKTLTE EEVEEVLRNI FKISLGRNLV PKPGDGSLTI
-
Cross-Reactivity
- Human, Mouse, Rat
-
Characteristics
- Polyclonal Antibodies
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 171-290 of human NAT2 (NP_000006.2).
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB,1:500 - 1:2000,IHC,1:50 - 1:200
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- NAT2 (N-Acetyltransferase 2 (Arylamine N-Acetyltransferase) (NAT2))
-
Alternative Name
- NAT2
-
Background
- This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2).,NAT2,AAC2,NAT-2,PNAT,Cancer,Signal Transduction,Endocrine & Metabolism,Drug metabolism,NAT2
-
Molecular Weight
- 33 kDa
-
Gene ID
- 10
-
UniProt
- P11245
Target
-